Cargando…
SARS-CoV-2 spike S2-specific neutralizing antibodies
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and authorized for emergency use to control the pandemic. Most COVID-19 therapeutic NAbs prevent the S1 subunit...
Autores principales: | Li, Chia-Jung, Chang, Shih-Chung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274517/ https://www.ncbi.nlm.nih.gov/pubmed/37254830 http://dx.doi.org/10.1080/22221751.2023.2220582 |
Ejemplares similares
-
Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022) -
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021) -
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021) -
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
por: Huang, Qingrui, et al.
Publicado: (2022) -
Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
por: Wang, Meiyu, et al.
Publicado: (2021)